Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapeutics for liver diseases and viral infections, including chronic hepatitis B virus (HBV), metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. Its pipeline features small molecule and oligonucleotide drug candidates designed to improve treatment outcomes by targeting viral lifecycles and metabolic pathways. Aligos leverages proprietary platforms, in-licensing, and internal expertise to create potentially best-in-class therapies for large unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.